Dr. Dicker is Chair & Professor of Radiation Oncology, Pharmacology and Experimental Therapeutics at Thomas Jefferson University. He was also appointed to the American Society for Radiation Oncology (ASTRO) Radiation Oncology Healthcare Advisory Council for the Radiation Oncology Incident Learning System (PSO). He is the Principal Investigator of the US Department of Defense (DoD) Prostate Synergy Grant, exploring the use of “smart needles” for diagnostic and therapeutic applications.
Dr. Dicker published numerous papers evaluating signal transduction agents with ionizing radiation and published “first in human” developmental therapeutic trials involving novel signal transduction agents and radiation therapy.
He serves as the co-Chair-Translational Science Committee for the National Cancer Institute (NCI) cooperative group. He also coordinates the creation of a NCI–RTOG Translational Program Strategic Guidelines for the Development of Radiosensitizers. He serves on the Clinical, Translational, and Basic Science Advisory Committee of ASTRO and he is past Chair of the Radiation and Cancer Biology Committee. In 2014, he was selected as a Fellow of ASTRO designation (FASTRO), for contributions to the field of radiation oncology in the areas of research, education, patient care, service, and leadership.
Dr. Dicker represents the NRG Oncology on the NCI’s Investigational Drug Steering Committee of CTEP and he is consultant on Cancer to the European Commission, the National Cancer Institute of Canada and the Italian Association of Cancer Research.